Wall Street analyst estimates for Nuvation Bio Inc. (NUVB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6.
Valuation Ratios
| Price / Book | 7.68 |
| EV / EBITDA | -15.36 |
| Dividend Yield | 0.00% |
Price
| Price | $5.78 |
| Market Cap | $2.0B |
| Exchange | NYSE |
| Country | US |
Related companies: ABCL · AUPH · CLDX · EWTX · GPCR · JANX · OCUL
Explore sector: Healthcare · Biotechnology
More sections of NUVB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks